Phacilitate Leaders Forum

29TH - 30TH SEPTEMBER 2020



Fiona Thistlethwaite

Fiona Thistlethwaite

Medical Oncology Consultant, The Christie NHS Foundation Trust and Director, iMATCH

Dr Fiona Thistlethwaite is a Medical Oncology Consultant within the ECMT (Experimental Cancer Medicines Team) at The Christie NHS Foundation Trust and Honorary Senior Lecturer at The University of Manchester. She graduated from The University of Cambridge MB PhD programme in 1999. Her PhD, under the supervision of Professor Sir Martin Evans, explored the molecular mechanisms that lead to cancer in inherited breast cancer syndromes. Following posts at Liverpool Royal, The Royal Marsden and The Christie she became a consultant at The Christie in 2007 and joined the ECMT in 2016. Fiona has been actively involved in clinical trial development for many years with a research focus on early phase clinical trials in immune-oncology, particularly adoptive cell therapies, combination immunotherapies and immune biomarkers. She has experience as principal and chief investigator of adoptive cell therapy trials including CAR T, TCR T cell and non-gene modified T cells across a range of tumour types. Fiona is the Programme Director for the iMATCH (Innovate Manchester Advanced Therapy Centre Hub) consortium which has the aim of scaling up of advanced therapies across Manchester and beyond. iMATCH was awarded almost £7M in 2018 to become one of three Innovate UK funded ATTC (Advanced Therapy Treatment Centres). She is also project lead for the multi-million pound ATTC network project SAMPLE which is focussing on standardisation of starting materials for cellular therapies. Fiona is a founding member of the IUK funded ATTC Network Steering Committee and has been a member of the ESMO Congress Scientific Committee (Immunotherapy Track) for the last 4 years.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd